

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): January 12, 2026

SI-BONE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-38701
(Commission
File Number)

26-2216351
(I.R.S. Employer
Identification No.)

**471 El Camino Real
Suite 101
Santa Clara, CA 95050**
(Address of principal executive offices) (Zip Code)

(408) 207-0700
(Registrant's telephone number, include area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Stock, par value \$0.0001 per share

Trading Symbol(s)
SIBN

Name of each exchange on which registered
The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, SI-BONE, Inc. (the "Company") issued a press release (the "Press Release") announcing preliminary unaudited revenue and cash and equivalents for the fourth quarter and full year 2025. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

Members of the Company's management team expect to meet with investors and analysts the week of January 12, 2026, to discuss the Company performance, using presentation materials which are furnished and attached as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated January 12, 2026
99.2	Presentation dated January 12, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2, of this Current Report on Form 8-K are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (Exchange Act), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (Securities Act). The information in Items 2.02 and 7.01, and Exhibits 99.1 and 99.2 shall not be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SI-BONE, INC.

Date: January 12, 2026

By: /s/ Anshul Maheshwari
Anshul Maheshwari
Chief Financial Officer
(Principal Financial and Accounting Officer)



SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fiscal Year 2025 worldwide revenue of \$200.8 to \$200.9 million, representing growth of ~20%

SANTA CLARA, Calif., January 12, 2026 – SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2025.

Fourth Quarter 2025 Summary *(any comparisons are to the prior year period)*

- Worldwide revenue between \$56.2 - \$56.3 million, representing ~15% growth
- U.S. revenue between \$53.3 - \$53.4 million, representing ~14% growth
- ~1,640 active physicians in the U.S., an increase of 250 physicians, representing ~18% growth
- Cash and equivalents of ~\$147.7 million, implying net cash generation of ~\$2.0 million in the quarter

Fiscal Year 2025 Summary *(any comparisons are to the prior year period)*

- Worldwide revenue between \$200.8 - \$200.9 million, representing ~20% growth
- U.S. revenue between \$190.9 - \$191.0 million, representing ~21% growth

The fourth quarter and full year 2025 revenue and cash and equivalents are included in this release on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2025 financial results during its fourth quarter 2025 earnings call in late February 2026.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Forward Looking Statements

The statements in this press release regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's preliminary fourth quarter and full year 2025 revenue and cash and cash equivalents, which are subject to continued review by SI-BONE and its auditors and significant adjustments may be made before final results are determined, SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.S. trading partners on the ability and desire of patients to undergo elective procedures including those using SI-BONE's products, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE's most recent filings on Form 10-K and Form 10-Q, and SI-BONE's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.


Investor Contact

Saqib Iqbal

VP, FP&A, and Investor Relations
investors@SI-BONE.com

**SI-BONE
Corporate Overview**

January 2026



Forward-Looking Statements

The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's preliminary fourth quarter and full year 2025 revenue and cash and cash equivalents, which are subject to continued review by SI-BONE and its auditors and significant adjustments may be made before final results are determined, SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.S. trading partners on the ability and desire of patients to undergo elective procedures including those using SI-BONE's products, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE's most recent filings on Form 10-K and Form 10-Q, and SI-BONE's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.



Financial Update

Key Highlights – Record Performance

Fourth Quarter 2025

- ~15% worldwide revenue growth: \$56.2 to \$56.3 million
- ~14% U.S. revenue growth: \$53.3 to \$53.4 million
- ~18% growth in U.S. active physicians

Fiscal Year 2025

- ~20% worldwide revenue growth: \$200.8 to \$200.9 million
- ~21% U.S. revenue growth: \$190.9 to \$191.0 million

+20% Revenue CAGR
Since IPO (2018)

Net Cashflow Breakeven
Third consecutive quarter

~250
U.S. physicians added in 4Q

Note: The fourth quarter and full year 2025 revenue and cash and equivalents are included on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment.
Note: As of December 31, 2025
Note: All comparisons are versus Fourth Quarter 2024 and Fiscal Year 2024


Strong Demand Drove Record Revenue in 2025



Note: As of December 31, 2025

Note: The fourth quarter and full year 2025 revenue and cash and equivalents are included on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment.

Record Physician Engagement Driving Procedure Demand



5 consecutive years of double-digit U.S. active physician growth every quarter

Broad-based volume growth across all procedure types

Note: As of December 31, 2025
Note: Rounded for presentation purposes.

Long-Term Business Drivers

Platform Set-up to Deliver Strong Revenue Growth and Operating Leverage

Innovation <i>Build differentiated portfolio</i>	Accelerate penetration of <i>iFuse Bedrock Granite</i> in adult deformity & degeneration market Build pelvic trauma with <i>iFuse TORQ TNT</i> and interventional market with <i>iFuse TORQ</i> and <i>iFuse INTRA</i>
Physician Engagement <i>Drive penetration and adoption</i>	Leverage training and comprehensive portfolio to drive physician growth and density Expand residents and fellows academic training programs
Commercial Execution <i>Accelerate market expansion</i>	Expand sales force headcount Deploy hybrid case coverage solutions
Operational Excellence <i>Expand Profitability</i>	Increase revenue per territory Optimize cost of surgical capacity

>\$3B Opportunity | Breakthrough Products | Differentiated Health Economics | Scalable Infrastructure | Strong Liquidity

Differentiated Portfolio Complemented By Strong Fundamentals

Robust Data	200+ published papers 4 Randomized Controlled Trials
Reimbursement Advantage	TPT for iFuse Bedrock Granite NTAP for iFuse TORQ TNT
Large, Underpenetrated Markets	470,000 annual target procedures, for a total annual opportunity > \$3.5 billion <10% total addressable market penetrated
Strong Execution Track Record	5 Years of double-digit U.S. active physician base growth Third Breakthrough Device under development
Proven Operational Excellence	20%+ Revenue CAGR – since IPO (2018) 3 rd consecutive quarter of net cashflow breakeven

>\$3B Opportunity | Breakthrough Products | Differentiated Health Economics | Scalable Infrastructure | Strong Liquidity

Note: As of December 31, 2025



Company Overview

Market Leading Platform For Compromised Bone Procedural Solutions



Innovation

3 Breakthrough Designated Devices
72 WW Patents



Evidence

4 Randomized Controlled Trials^{1,2}
200+ Peer-reviewed Publications³



Education

~1,640 Active US Physicians^{5,6}
140,000+ Procedures Performed⁷



Commercialization

89 Territory Managers
400+ CSS and Agents

>\$3B Opportunity | **Breakthrough** Products | **Differentiated** Health Economics | **Scalable** Infrastructure

Note: As of December 31, 2025.

1. Polly DW, et al. Int J Spine Surg. 2016 Aug 23;10:28. [INSITE 2yr]
2. Dengler J, et al. J Bone Joint Surg Am. 2019;101(5):400-11. [MIA 2yr]
3. <https://si-bone.com/results>

5. Physicians who performed a procedure in the quarter.
6. Physicians encompasses surgeons and interventionalists.
7. As of December 31, 2025. Procedures worldwide with SI-BONE products since inception of the company.

Large Addressable Markets with Attractive Fundamentals




Three Large Unmet Clinical Needs In Sacropelvic Conditions

SI Joint Dysfunction

15-30% Chronic LBP is SI Joint ¹


High Burden of Disease ²



Pelvic Trauma

27% Mortality from Bedrest, Downward Spiral ³


14-41% Rate of Screw Loosening/Backout ⁴



Sacropelvic Fixation

24% Rate of Failure ASD Surgery ⁵

28% SI Joint Issues Post Spinal Fusion ⁶



1. Bernard – Clin Orthop Relat Res 1987; Schwarzer – Spine 1995; Maigne – Spine 1996; Irwin – Am J Phys Med Rehabil 2007; Sembrano – Spine 2009.
2. Cher – Med Devices (Auckl) 2014.
3. Morris – Postgrad Med J 2000.

4. Wong – J Ortho Surg (Hong Kong) 2019; Kim – Arch Orthop Trauma Surg 2016; Eckardt – Injury 2017; Reuther – Rofo 2014.
5. Eastlack – Spine 2022.
6. Manzetti – Clin Spine Surg 2023.
7. Ivanov – Spine 2009

Innovation Driven Differentiated Platform

iFuse INTRA™

*Intra-articular
Stabilization & Fusion*

- Small surgical profile
- Long length increases joint contact
- Intra-articular placement improves stabilization*



iFuse TORQ® iFuse TORQ TNT™

*Cutting-Edge Pelvic Fixation
& Fusion; and Fragility Fractures*


- TORQLock™ reduces toggle
- EZDrive® decreases surgical steps
- IntelliHarvest® self-harvests bone



iFuse 3D™ iFuse

*Market Leader in
SI Joint Fusion*

- 6x > rotational resistance vs. screws²
- 2 RCTs, 140+ Peer-reviewed studies³
- Promotes osseointegration⁴



iFuse Bedrock Granite®

*Breakthrough Fixation,
Fusion, Foundation*

- Higher pull-out strength vs. Solera⁵
- Facilitates osseointegration
- Largest neck on the market



SI Joint Dysfunction

Pelvic Trauma

Sacropelvic Fixation

1. SI-BONE Technical Study 301310-TS.
2. SI-BONE Technical Study 300610-TS.
3. Polly – IJSS 2016; Dengler – JBJS Am 2019; <https://si-bone.com/results>
4. MaxBarb – IJSS 2019 (Part 2).
5. SI-BONE Technical Study 301098-TS.

* Biomechanical and animal studies not necessarily indicative of human clinical outcomes.

Patent Protected Differentiated Platform

▪ 72 issued patents: U.S. (49), OUS (23)

▪ 47 pending patents: U.S. (24), OUS (23)

- iFuse 3D™ implant patents until Sept 2035
- Triangular broach instrument patent until Feb 2034
- iFuse implant patent until May 2026

INSTRUMENT



Triangular broach instrument and the methods of using the instrument


3-D TECHNOLOGY



Rectilinear profile, longitudinal struts, and struts connecting the longitudinal struts


- iFuse TORQ® implant patent until Feb 2041
- iFuse Bedrock Granite® implant patent until Feb 2039

iFuse Bedrock Granite



Inner shank with external distal threads and an outer sleeve with threads, surface growth features, and fenestrations

iFuse TORQ



Helical threads, porous network of struts disposed between the threads, and the porous height is less than the major thread diameter


Note: As of December 31, 2025




Portfolio Overview

Sacroiliac Joint Dysfunction Treatments

Non-surgical Management



Procedures



Proprietary, Differentiated *iFuse Technology*[®]

	
Rotation	▲ 6x resistance (vs. 12mm Rialto screw) ¹
Strength	▲ 3x strength (vs. stand 8.0mm cannulated screw) ²
Safety	▲ Low complication rate ^{3,4}
Revision	▲ 3.5% (4-year) ⁵
Clinical Evidence	▲ 2 RCTs ⁶
Surface	▲ Porous 

- ▶ Proven triangular design and procedure
- ▶ Porous, 3D-printed titanium implant
- ▶ Bony on-growth, in-growth, and through-growth⁷

1. SI-BONE Technical Study 300610-TS. Torsional Rigidity of the iFuse Implant Compared with a SI Joint Screw in a Sawbones Model.
 2. SI-BONE Report. Strength of materials of the SI-BONE iFuse Implant vs. 8.0 mm Cannulated Screw. Mauldin RG. December 2009.
 3. SI-BONE Corporate Records. Complaining Handling & Post-market Surveillance. September 2024.

4. Whang – Int J Spine Surg 2023.
 5. Cher – Med Devices (Auckl) 2015.
 6. Poly – Int J Spine Surg 2016 [NSRTE 2yr]; Dengler – J Bone Joint Surg Am 2019 [MIA 2yr].
 7. MacBarb – Int J Spine Surg 2017 (Part 2).

REPRESENTATIVE COMPETITOR



TPS-COATED iFUSE



CANCELLOUS BONE



3D-PRINTED iFuse 3D





3 MONTH SHEEP STUDY⁷



SALLY Prospective Clinical Trial: iFuse 3D 5-year Outcomes¹

Rapid, marked and durable improvements in pain, patient function and quality of life



VAS Pain Reduction	58-point improvement (MCID 20 points)
ODI Disability Improvement	25-point improvement (MCID 15 points)
Decreased Opioid Use	57% at baseline vs. 17% at follow-up
Patient Satisfaction	94% satisfied / very satisfied at follow-up



1. Patel V, et al. Prospective Trial of Sacroiliac Joint Fusion Using 3D-Printed Triangular Titanium Implants: 5-Year Follow-Up. Spine. 2024 Sep 30. [51 subjects enrolled and treated between October 2017 and January 2019. 60-month follow-up was obtained in 36 (71%)]

2. Similar results to RCTs (INSITE and IMIA) and Prospective trial SIFI.

3. Three tests (active straight leg raise, 5x sit-to-stand, transitional timed up-and-go).

4. CT at 60 months [Patel – Spine 2024]

iFuse TORQ®: Cutting-Edge Pelvic Fixation and Fusion™

Large, Adjacent Market ¹

>\$300 million Pelvic Trauma opportunity

~120K Sacral Fragility fracture incidence / yr.

Differentiated Technology

FuSion 3D™ Surface for Osseointegration

IntelliHarvest® Technology self harvests host bone

Competitive Advantages

TORQLock™ Threads²

10x rotational resistance on insertion vs. trauma screws




1. Based on internal estimates.
2. Internal clinical reports. Data on file.

iFuse TORQ TNT™: Pelvic Bone Density-Driven Design



- Through 'N Through™' ("TNT")¹
- FDA Breakthrough Device Designation²
- Pelvic fragility fracture fixation
- Pelvic-specific 8.7mm diameter
- 3D-printed porous lattice surface designed for osseointegration

FDA Clearance
September 2024




CMS FY2026 IPPS New Technology Add-On Payment ("NTAP") of up to \$4,136

1. The first 3D-printed, porous threaded implant with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.
2. The FDA determined iFuse TORQ TNT has the potential to provide more effective fixation of pelvic fragility fractures than the current standard of care, cannulated screws.

iFuse Bedrock Granite®: *Fixation. Fusion. Foundation.*™



Differentiated Technology



Microporous Lattice Surfaces



Macroporous Fenestrations
IntelliHarvest® Cutting Flutes



OMNISCapture™ Tulip & Set Screw



EZDrive® Tip

Large, Adjacent Market

~\$1 billion Adult Spinal Deformity and Degenerative Spine pelvic fixation opportunity¹

Competitive Advantages

Breakthrough Device Designation by the FDA
Proposed extension of **Transitional Pass-Through (TPT)** Payment status for FY26

1. Based on management estimate of total addressable market for existing and potential products in 2024.

iFuse Bedrock Granite[®] – 9.5mm Diameter Implant

FDA Clearance
January 2024

- Line extension of our breakthrough implant
- Smaller diameter (9.5mm)
- 3D-printed lattice & surface technology
- Additional application for use in S1 trajectory and pediatric deformity¹



1. 510(k) Clearance – K233508 (Jan 2024)

Disclosures

The **iFuse Bedrock Granite**® Implant System is intended for sacroiliac joint fusion in skeletally mature patients for the following conditions:

- Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
- To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
- Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.

When connected to compatible pedicle screw systems with 5.5- or 6.0-mm posterior rods made from either titanium alloy or cobalt chrome alloy the iFuse Bedrock Granite Implant System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to thoracolumbosacral fusion for the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine:

- Degenerative disc disease (DDD) as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies
- Spondylolisthesis
- Trauma (i.e., fracture or dislocation)
- Spinal stenosis
- Deformities or curvatures (i.e., scoliosis, kyphosis, and/or lordosis)
- Spinal tumor
- Pseudarthrosis
- Failed previous fusion

When connected to compatible pedicle screws with 5.5- or 6.0-mm posterior rods made from either titanium alloy or cobalt chrome alloys, the iFuse Bedrock Granite Implant System is intended to provide immobilization and stabilization of spinal segments in skeletally immature patients as an adjunct to thoracolumbar fusion for the treatment of progressive spinal deformities (i.e., scoliosis, kyphosis, or lordosis) including idiopathic scoliosis, neuromuscular scoliosis, and congenital scoliosis, as well as the following conditions: spondylolisthesis/spondylolysis, fracture caused by tumor and/or trauma, pseudarthrosis, and/or failed previous fusion. These devices are to be used with autograft and/or allograft. Pediatric pedicle screw fixation is limited to a posterior approach.

Please refer to the additional information section in the Instructions for Use on compatible pedicle screw system rods.

The iFuse Bedrock Granite Navigation instruments are intended to be used with the iFuse Bedrock Granite Implant System to assist the surgeon in precisely locating anatomical structures in iFuse Bedrock Granite Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data based model of the anatomy. iFuse Bedrock Granite Navigation instruments are intended to be used with the Medtronic® StealthStation® System.

Disclosures

The **iFuse TORQ®** Implant System is indicated for:

- Fusion of the sacroiliac joint for sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis.
- Fracture fixation of the pelvis, including acute, non-acute and non-traumatic fractures.

The iFuse TORQ Implant System is also indicated for fracture fixation of the pelvis, including acute, non-acute, and non-traumatic fractures.

The iFuse TORQ Navigation instruments are intended to be used with the iFuse TORQ Implant System to assist the surgeon in precisely locating anatomical structures in iFuse TORQ Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data based model of the anatomy. iFuse TORQ Navigation instruments are intended to be used with the Medtronic® StealthStation® System.

The **iFuse TORQ TNT™** Implant System is indicated for fracture fixation of the pelvis, including acute, non-acute and non-traumatic fractures.

The iFuse TORQ TNT Implant System is indicated for sacroiliac joint fusion for sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis.

The iFuse TORQ TNT Navigation Instruments are intended to be used with the iFuse TORQ TNT Implant System to assist the physician in precisely locating anatomical structures in iFuse TORQ TNT Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data based model of the anatomy. iFuse TORQ TNT Navigation Instruments are intended to be used with the Medtronic StealthStation System.

Disclosures

The **iFuse Implant System**[®] is intended for sacroiliac fusion for the following conditions:

- Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
- To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropevic fixation as part of a lumbar or thoracolumbar fusion.
- Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.

If present, a pelvic fracture should be stabilized prior to the use of iFuse implants.

The **iFuse INTRA**[™] Allograft Implant System instruments are indicated for placement of the iFuse Bone allograft.


The iFuse INTRA Allograft Implant System is indicated for homologous use.

Healthcare professionals please refer to the Instructions For Use for indications, contraindications, warnings, and precautions at <https://si-bone.com/label>.

There are potential risks associated with iFuse procedures. They may not be appropriate for all patients, and all patients may not benefit. For information about the risks, visit: <https://si-bone.com/risks>.

SI-BONE, Sacropevic Solutions, iFuse Implant System, iFuse Technology, Bedrock, iFuse Bedrock Granite, iFuse TORQ, iFuse Bone, EZDrive, and IntelliHarvest are registered trademarks of SI-BONE, Inc.

iFuse 3D, SI-BONE Simulator, FuSton 3D, TORQLock, iFuse INTRA, iFuse TORQ TNT, and Through 'N Through are trademarks of SI-BONE, Inc.
© 2026 SI-BONE, Inc. All rights reserved.



Pioneering Procedural Solutions
For Compromised Bone®

140,000+
Procedures

72+
Patents

200+
Publications

Note: As of December 31, 2025

